SCYNEXIS, Inc. Financing Receivable, Allowance for Credit Loss
SCYNEXIS, Inc. (SCYX) had Financing Receivable, Allowance for Credit Loss of $0 as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Balance Sheet › Assets
us-gaap:FinancingReceivableAllowanceForCreditLosses · last filed 2023-11-13
- 2023-09-30: Financing Receivable, Allowance for Credit Loss $0.00.
- 2023-06-30: Financing Receivable, Allowance for Credit Loss $0.00.
- 2023-03-31: Financing Receivable, Allowance for Credit Loss $0.00.
| Period end | Financing Receivable, Allowance for Credit Loss |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |